Lin T Z, Fernandes H, Yauch R, Ponzio N M, Raveche E
Department of Laboratory Medicine and Pathology, UMDNJ-New Jersey Medical School, Newark 07103.
Clin Immunol Immunopathol. 1992 Oct;65(1):10-22. doi: 10.1016/0090-1229(92)90242-g.
A majority of SJL mice develop spontaneous reticulum cell sarcomas (RCS) at about 1 year of age which can be transplanted into young SJL recipients. Previous studies have shown that RCS tumors are of B cell lineage, and that the development of these lymphomas and their subsequent growth depends upon host-derived T helper cell factors. In vivo treatment of SJL mice with anti-CD4 monoclonal antibody (mAb) prevents the development of the characteristic B lymphomas. Most of the mAb-treated animals were tumor free and had a significantly prolonged life span. However, one such CD4 mAb-treated mouse developed a transplantable IgM+ CD5+ B cell lymphoma (designated NJ101), which has not previously been described in SJL/J mice. NJ101 is clonal on the basis of a discrete non-germ line Ig heavy chain gene rearrangement by Southern blot analysis. Unlike the sIg- CD5- transplantable RCS-X cell line, the IgM+ CD5+ NJ101 lymphoma cells will grow in immuno-compromised hosts, such as irradiated recipients or in recipients treated with CD4 mAb in vivo. The RCS (B cell) lymphoma requires CD4+ T cells for progressive growth, whereas the growth of the CD5+ B lymphoma cells is enhanced by the removal of such cells. Thus, CD5+ B cell clonal development may be aided by the removal of regulatory T cells and/or the malignant CD5+ B cells may produce their own growth factors in an autocrine manner. Examination of IL-10 message by quantitative polymerase chain reaction techniques indicate that the CD5+ B lymphoma cells produce increased levels of IL-10 relative to normal LN cells or purified RCS lymphoma cells. These results suggest that two different types of B cell tumors, both of which can develop in SJL mice, have different growth requirements. Furthermore, treatment to prevent the occurrence of the characteristic RCS malignancy of SJL mice may lead to the development of another form of B cell neoplasia.
大多数SJL小鼠在约1岁时会自发发生网状细胞肉瘤（RCS），这些肿瘤可移植到年轻的SJL受体中。先前的研究表明，RCS肿瘤属于B细胞谱系，并且这些淋巴瘤的发生及其后续生长依赖于宿主来源的T辅助细胞因子。用抗CD4单克隆抗体（mAb）对SJL小鼠进行体内治疗可预防特征性B淋巴瘤的发生。大多数接受mAb治疗的动物无肿瘤，且寿命显著延长。然而，一只接受这种CD4 mAb治疗的小鼠发生了一种可移植的IgM + CD5 + B细胞淋巴瘤（命名为NJ101），此前在SJL / J小鼠中尚未有过描述。通过Southern印迹分析，基于离散的非胚系Ig重链基因重排，NJ101是克隆性的。与sIg- CD5-可移植的RCS-X细胞系不同，IgM + CD5 + NJ101淋巴瘤细胞可在免疫受损宿主中生长，如经照射的受体或体内接受CD4 mAb治疗的受体。RCS（B细胞）淋巴瘤的进行性生长需要CD4 + T细胞，而去除此类细胞可增强CD5 + B淋巴瘤细胞的生长。因此，去除调节性T细胞可能有助于CD5 + B细胞的克隆发育，和/或恶性CD5 + B细胞可能以自分泌方式产生自身生长因子。通过定量聚合酶链反应技术检测IL-10信息表明，相对于正常淋巴结细胞或纯化的RCS淋巴瘤细胞，CD5 + B淋巴瘤细胞产生的IL-10水平升高。这些结果表明，两种不同类型的B细胞肿瘤，均可在SJL小鼠中发生，具有不同的生长需求。此外，预防SJL小鼠特征性RCS恶性肿瘤发生的治疗可能会导致另一种形式的B细胞肿瘤形成。
